Black Diamond Therapeutics, Inc. (BDTX)

Over the past six months, BDTX's stock has trended down. In December 2025, the company announced preliminary Phase 2 data for silevertinib, leading to a stock price decrease. In March 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results and participated in investor conferences. Despite the stock decline, some analysts maintain a 'Buy' rating, citing the EGFR inhibitor pipeline and strong financial position.

As a clinical-stage oncology company, Black Diamond Therapeutics does not experience traditional demand seasonality. Its valuation is driven by clinical trial readouts, regulatory milestones, and market sentiment rather than seasonal fluctuations in product demand.

Black Diamond Therapeutics is a clinical-stage oncology company focused on developing MasterKey therapies for genetically defined cancers. Their approach involves creating small-molecule inhibitors that target families of oncogenic mutations across various tumor types. Silevertinib is a brain-penetrant EGFR MasterKey inhibitor in Phase 2 trials for NSCLC and GBM, showing promise in patients resistant to earlier treatments. BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations, is in Phase 1 trial and has been out-licensed to Servier. BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations, is in the preclinical stage.

Black Diamond Therapeutics is headquartered in Cambridge, Massachusetts, United States. Its operations are centered on research, clinical development, and related corporate and partnering efforts.

Black Diamond Therapeutics' reputation is tied to the progress of its pipeline, particularly silevertinib. Despite a stock price decline, some analyses consider the company 'undervalued' due to its EGFR inhibitor pipeline. Positive Phase 2 data for silevertinib has been viewed optimistically, and the company's financial position contributes to a stable outlook.

Black Diamond Therapeutics has a diverse ownership structure including institutional investors, insiders, and retail investors. Major institutional owners include T. Rowe Price Investment Management, Inc., NEA Management Company, LLC, and Vanguard Group Inc. Ali Behbahani owns the most shares among individual investors.